Astrocytoma, Grade IV

Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy

UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-4

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma

ALBATROSS Study: International Multicenter Study for Prospective Validation of Imaging Biomarkers Calculated at Vascular Habitats of High-grade Gliomas

BIOhabitats: Biological Validation of Vascular Habitats Within Astrocytoma Grade 4 at Molecular, Cellular, and Histopathological Levels

A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM

Study of Olutasidenib and Temozolomide in HGG

Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme

T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma

The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)

The SAFE-Trial: Awake Craniotomy Versus Surgery Under General Anesthesia for Glioblastoma Patients.

The Addition of Chloroquine to Chemoradiation for Glioblastoma,

Coaching for Coping in Glioblastoma Patients and Caregivers and Its Association With Compliance to TTFields

Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma

DC Migration Study for Newly-Diagnosed GBM

Study of Stereotactic Radiosurgery to the Subventricular Zone in Malignant Gliomas

CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type

Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma